Clinical Trial Protocol
Iranian Registry of Clinical Trials

25 Jun 2026

The comparison effect of memantin in improvement of quality of life and global function in patients with schizophrenia

Protocol summary

Summary

This study is clinical trial double blind (patients and researcher)placebo control that evaluate the efficacy of memantine in treatment of schizophrenia.Criteria for inclusion:age group 18-65 years old;no pregnancy or milking;no mental retardation.Criteria for exclusion: allergy to memantine; drug or substance abuse or dependency. 64 patients with schizophrenia divided into two groups:intervention and control.both of 2 groups receive one atypical anti psychotic, in addition patients in intervention group receive memantin and in control group receive placebo. in intervention group ,memantin start with 5mg per day ,and it's dose increases 5mg weekly ,after 4 weeks,it will be 20 mg per day. clinical assessment perform in baseline and each 4 weeks to 12 weeks,using positive and negative syndrome scale(PANSS),Quality Of Life Scale (QLS),Global Assessment Of Functioning (GAF),Calgary Depressive Scale for Schizophrenia (CDSS).

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2014092819320N1**
Registration date: **2014-11-01, 1393/08/10**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2014-11-01, 1393/08/10

Registrant information

Name
Maryam Mohammadian Sichani
Name of organization / entity
Isfahan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 31 3335 9467
Email address
farshid5@sepahan.iut.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research of Isfahan Univercity of Medical science

Expected recruitment start date

2013-07-06, 1392/04/15

Expected recruitment end date

2014-03-11, 1392/12/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The comparison effect of memantin in improvement of quality of life and global function in patients with schizophrenia

Public title

Effect of memantin in treatment of patients with schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

inclusion criteria:age group 18-65 ; no mental retardation ;no pregnancy or milking ;diagnosis of schizophrenia for at least 2 years;treatment with atypical anti psychotic from 3 month ago;do not have ECT during 2 week ago Exclusion criteria:allergic to memantin;addiction or dependency to substance or drugs ;other psychiatric disorder or serious neurological deficit.

Age
From **18 years** old to **65 years** old
Gender
Both

Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **64**
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Isfahan Univercity of Medical Sciences
Street address
Isfahan Univercity of Medical Science,Aven Hezar Jerib وIsfahan,IRAN
City
Isfahan
Postal code
Approval date
2013-05-29, 1392/03/08
Ethics committee reference number
392220

Health conditions studied

1

Description of health condition studied
schizophrenia
ICD-10 code
F20,F21,F2
ICD-10 code description
Schizophrenia, schizotypal and delusional disorder

Primary outcomes

1

Description
Quality of life
Timepoint
at base line,each 4 weeks to 12weeks
Method of measurement
Quality Of Life scale of schizophrenia

2

Description
Global Function
Timepoint
at baseline,each 4 weeks to 12weeks
Method of measurement
Global Assesment Of Functioning

3

Description
Possitive and negative symptoms
Timepoint
at base line, each 4 weeks to12 weeks
Method of measurement
Possitive And Negative Symptom Scale

4

Description
Depression
Timepoint
at base line,each 4 weeks to12 weeks
Method of measurement
Calgary Depressive Scale for Schizophrenia

Secondary outcomes

1

Description
side effects
Timepoint
during 12 weeks of study
Method of measurement
history of patient and his/her companion and physical exam

Intervention groups

1

Description
control group:placebo tablet that is similar to memantin in shape,size and color. starting with single dose 5mg per day then increase 5mg each week ,up to 10 mg at morning and 10 mg at night after 4 weeks and continuation (10 mg BD)to12 weeks.
Category
Placebo

2

Description
study group : memantine tab,starting with single dose

5mg per day then increase 5mg each week ,up to 10 mg at morning and 10 mg at night after 4 weeks and continue (10 mg BD)to12 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Noor Hospital

Full name of responsible person

Mohammadian Sichani Maryam

Street address

Noor Hospital, Isfahan, Iran

City

Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research of Isfahan Univercity of Medical science

Full name of responsible person

Dr Ciavash,Manager of Vice chancellor for research of Isfahan Univercity of Medical science

Street address

Isfahan Univercity of Medical Science,Avenue HezarJerib, Isfahan, Iran

City

Isfahan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research of Isfahan Univercity of Medical science

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Mohammadian Sichani Maryam

Position

Resident of Psychiatric

Other areas of specialty/work

Street address

University of medical Sciences, avenue Hezar jeribe, Isfahan, Iran

City

Isfahan

Postal code

Phone

+98 31 3222 2475

Fax

Email

farshid5@sepahan.iut.ac.ir; Mohammadian99@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Isfahan Univercity of Medical Science

Full name of responsible person

Mohammadian Sichani Maryam

Position

Resident of psychiatric

Other areas of specialty/work

Street address

Univercity of Medical Science, Avenue Hezar jerib, Isfahan, Iran

City

Isfahan

Postal code

Phone

+98 31 3222 2475

Fax

Email

farshid5@sepahan.iut.ac.ir ; Mohammadian99@Yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Isfahan University of Medical Sciences

Full name of responsible person

Mohammadian Sichani Maryam

Position

Resident of Psychitric

Other areas of specialty/work

Street address

City

Isfahan

Postal code

Phone

+98 31 3222 2475

Fax

Email

farshid5@sepahan.iut.ac.ir;

Mohammadian99@Yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty

Study Protocol
empty

Statistical Analysis Plan
empty

Informed Consent Form
empty

Clinical Study Report
empty

Analytic Code
empty

Data Dictionary
empty